publication date: May. 25, 2018

Funding Opportunities

DOD Prostate Cancer Research Program opportunities published

The FY18 Defense Appropriations Act provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.

FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on

Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

Develop treatments that improve outcomes for men with lethal prostate cancer

Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

Define the biology of lethal prostate cancer to reduce death

Improve the quality of life for survivors of prostate cancer

Impact Award

Preproposal due July 19, 2018

Independent investigators at or above the level of Assistant Professor (or equivalent) 

Preproposal is required; application submission is by invitation only.

Supports research projects that have the strong potential to make a major impact on scientific and clinical prostate cancer issues

Must address at least one of the FY18 PCRP Overarching Challenges.

The potential impact of the research is expected to be near-term, with the potential to transform the clinical management of prostate cancer within 5 years after the end of the award.

Proposed projects may include basic, translational, or clinical research, including small scale clinical trials.

Detailed transition plan to describe the pathway for moving the project’s findings to the next phase of development after the award is required.

Preliminary data to support feasibility are required.

Maximum funding of $750,000 for direct costs (plus indirect costs).

Maximum period of performance … Continue reading DOD Prostate Cancer Research Program opportunities published

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.